| Adrianne Mary Rivera, LCSW | |
|
3843 Harding Blvd, Baton Rouge, LA 70807-5224 | |
| (225) 359-9315 | |
| (225) 359-9326 |
| Full Name | Adrianne Mary Rivera |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 28 Years |
| Location | 3843 Harding Blvd, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033270590 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 4504 (Louisiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Capital Area Human Services District | 2769450733 | 25 |
News Archive
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis.
Unlike their visual cousins, the neurons that control movement are not a predictable bunch. Scientists working to decode how such neurons convey information to muscles have been stymied when trying to establish a one-to-one relationship between a neuron's behavior and external factors such as muscle activity or movement velocity.
Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.
Many of the choices we make are informed by experiences we've had in the past. But occasionally we're better off abandoning those lessons and exploring a new situation unfettered by past experiences.
› Verified 1 days ago
| Entity Name | Capital Area Human Services District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174681852 PECOS PAC ID: 2769450733 Enrollment ID: O20081118000007 |
News Archive
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis.
Unlike their visual cousins, the neurons that control movement are not a predictable bunch. Scientists working to decode how such neurons convey information to muscles have been stymied when trying to establish a one-to-one relationship between a neuron's behavior and external factors such as muscle activity or movement velocity.
Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.
Many of the choices we make are informed by experiences we've had in the past. But occasionally we're better off abandoning those lessons and exploring a new situation unfettered by past experiences.
› Verified 1 days ago
| Entity Name | Capital Area Human Services District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710047980 PECOS PAC ID: 2769450733 Enrollment ID: O20081118000023 |
News Archive
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis.
Unlike their visual cousins, the neurons that control movement are not a predictable bunch. Scientists working to decode how such neurons convey information to muscles have been stymied when trying to establish a one-to-one relationship between a neuron's behavior and external factors such as muscle activity or movement velocity.
Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.
Many of the choices we make are informed by experiences we've had in the past. But occasionally we're better off abandoning those lessons and exploring a new situation unfettered by past experiences.
› Verified 1 days ago
| Entity Name | Capital Area Human Services District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730104654 PECOS PAC ID: 2769450733 Enrollment ID: O20100114000532 |
News Archive
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis.
Unlike their visual cousins, the neurons that control movement are not a predictable bunch. Scientists working to decode how such neurons convey information to muscles have been stymied when trying to establish a one-to-one relationship between a neuron's behavior and external factors such as muscle activity or movement velocity.
Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.
Many of the choices we make are informed by experiences we've had in the past. But occasionally we're better off abandoning those lessons and exploring a new situation unfettered by past experiences.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adrianne Mary Rivera, LCSW 3843 Harding Blvd, Baton Rouge, LA 70807-5224 Ph: (225) 359-9315 | Adrianne Mary Rivera, LCSW 3843 Harding Blvd, Baton Rouge, LA 70807-5224 Ph: (225) 359-9315 |
News Archive
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis.
Unlike their visual cousins, the neurons that control movement are not a predictable bunch. Scientists working to decode how such neurons convey information to muscles have been stymied when trying to establish a one-to-one relationship between a neuron's behavior and external factors such as muscle activity or movement velocity.
Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.
Many of the choices we make are informed by experiences we've had in the past. But occasionally we're better off abandoning those lessons and exploring a new situation unfettered by past experiences.
› Verified 1 days ago
Deanna Muse Roberts, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 8752 Quarters Lake Rd Bldg 9, Baton Rouge, LA 70809 Phone: 225-922-9122 Fax: 225-922-9125 | |
Stephanie Gordon, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 1900 S Acadian Thruway, Baton Rouge, LA 70808 Phone: 225-336-8700 | |
Darlene Cunningham, CSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4939 Jamestown Ave, Suite 101, Baton Rouge, LA 70808 Phone: 225-302-0500 | |
Kadario Derell Drumgoole, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3084 Westfork Dr Ste C, Baton Rouge, LA 70816 Phone: 225-296-6083 | |
John Bryant Lejeune, LMSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3455 Florida St, Baton Rouge, LA 70806 Phone: 225-256-6604 | |
Jacqueline Woods, LCSW-BACS Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 10473 Old Hammond Hwy, Baton Rouge, LA 70816 Phone: 225-924-1910 | |
Nancy B Bogan, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4615 Government St, Building 2, Baton Rouge, LA 70806 Phone: 225-925-1906 Fax: 225-925-1972 |